Marina Biotech Company Profile (OTCMKTS:MRNA)

About Marina Biotech (OTCMKTS:MRNA)

Marina Biotech logoMarina Biotech, Inc. is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. The Company's pipeline includes CEQ508, a product in clinical development for the treatment of Familial Adenomatous Polyposis (FAP), and preclinical programs for the treatment of type 1 myotonic dystrophy (DM1) and Duchenne muscular dystrophy (DMD). It creates a range of therapeutics targeting coding and non-coding ribonucleic acid (RNA) through several mechanisms of action, such as RNA interference (RNAi), messenger RNA translational inhibition, exon skipping, microRNA (miRNA) replacement, miRNA inhibition and steric blocking in order to modulate gene expression either up or down depending on the specific mechanism of action. It has two liposomal-based delivery platforms: SMARTICLES, and the platform, which utilizes amino-based liposomal delivery technology and incorporates a molecule, Di-Alkylated Amino Acid (DiLA2).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:MRNA
  • CUSIP: N/A
  • Web:
  • Market Cap: $34.01 million
  • Outstanding Shares: 97,169,000
Average Prices:
  • 50 Day Moving Avg: $0.37
  • 200 Day Moving Avg: $0.29
  • 52 Week Range: $0.08 - $0.48
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.04 per share
  • Price / Book: 8.75
  • Return on Equity: -79.82%
  • Return on Assets: -27.58%
  • Current Ratio: 0.15%
  • Quick Ratio: 0.15%
  • Average Volume: 37,367 shs.
  • Beta: 0.95
  • Short Ratio: 2.38
Frequently Asked Questions for Marina Biotech (OTCMKTS:MRNA)

What is Marina Biotech's stock symbol?

Marina Biotech trades on the OTCMKTS under the ticker symbol "MRNA."

How were Marina Biotech's earnings last quarter?

Marina Biotech Inc. (OTCMKTS:MRNA) posted its quarterly earnings data on Monday, November, 21st. The company reported ($0.05) EPS for the quarter. The firm had revenue of $0.05 million for the quarter. View Marina Biotech's Earnings History.

Who are some of Marina Biotech's key competitors?

Who are Marina Biotech's key executives?

Marina Biotech's management team includes the folowing people:

  • Vuong Trieu Ph.D., Executive Chairman of the Board
  • Joseph W. Ramelli, Chief Executive Officer, Secretary
  • Mihir Munsif, Chief Operating Officer
  • Larn Hwang Ph.D., Chief Scientific Officer
  • Erik Emerson, Chief Commercial Officer
  • Philippe Calais Ph.D, Director

How do I buy Marina Biotech stock?

Shares of Marina Biotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Marina Biotech's stock price today?

One share of Marina Biotech stock can currently be purchased for approximately $0.35.

MarketBeat Community Rating for Marina Biotech (OTCMKTS MRNA)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  14 (Vote Outperform)
Underperform Votes:  7 (Vote Underperform)
Total Votes:  21
MarketBeat's community ratings are surveys of what our community members think about Marina Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Marina Biotech (OTCMKTS:MRNA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Marina Biotech (OTCMKTS:MRNA)
DateFirmActionRatingPrice TargetDetails
10/26/2015Leerink SwannInitiated CoverageOutperformView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for Marina Biotech (OTCMKTS:MRNA)
Earnings by Quarter for Marina Biotech (OTCMKTS:MRNA)
Earnings History by Quarter for Marina Biotech (OTCMKTS MRNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/21/2016Q3 2016($0.05)$0.05 millionViewN/AView Earnings Details
11/17/2014Q3 14($0.28)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Marina Biotech (OTCMKTS:MRNA)
Current Year EPS Consensus Estimate: $-2.70 EPS


Dividend History for Marina Biotech (OTCMKTS:MRNA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Marina Biotech (OTCMKTS:MRNA)
Insider Ownership Percentage: 50.00%
Institutional Ownership Percentage: 0.01%
Insider Trades by Quarter for Marina Biotech (OTCMKTS:MRNA)
Insider Trades by Quarter for Marina Biotech (OTCMKTS:MRNA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/9/2017Vuong TrieuChairmanBuy10,000$0.39$3,900.00View SEC Filing  
6/7/2017Vuong TrieuChairmanBuy22,500$0.39$8,775.00View SEC Filing  
4/6/2017Joseph W RamelliCEOBuy35,500$0.39$13,845.00View SEC Filing  
4/5/2017Joseph W RamelliCEOBuy97,550$0.31$30,240.50View SEC Filing  
2/6/2017Vuong TrieuChairmanBuy862,068$0.29$249,999.72View SEC Filing  
4/16/2014Joseph W RamelliDirectorBuy26,300$0.76$19,988.00View SEC Filing  
2/10/2014Cashman Llp PryorMajor ShareholderSell108,041$0.99$106,960.59View SEC Filing  
10/4/2013Cashman Llp PryorMajor ShareholderSell100,000$0.25$25,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Marina Biotech (OTCMKTS:MRNA)
Latest Headlines for Marina Biotech (OTCMKTS:MRNA)
DateHeadline logoMarina Biotech Announces Binding Letter of Intent for the Sale of its DiLA2 Delivery Platform - July 26 at 1:11 AM logoMarina Biotech Acquires DyrctAxess™ Technology Platform to Support Sales and Marketing of Prestalia® - July 25 at 4:06 AM logoMarina Biotech up 11% on SMARTICLES license deal - July 20 at 1:44 AM logoMarina Biotech Announces a License Agreement to SMARTICLES and CRN platforms for Antisense DNA therapeutics - July 20 at 1:44 AM logoMarina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman - July 5 at 8:41 AM logoMarina Biotech Appoints Chief Commercial Officer to Lead Sales and Marketing of Prestalia(R) - June 26 at 8:59 AM logoMarina Biotech Acquires Prestalia(R), a U.S. FDA Approved Drug for Patients Whose Blood Pressure Is Not Adequately Controlled by Monotherapy - June 6 at 9:12 AM logoMarina Biotech to Participate in the 7th Annual LD Micro Invitational on June 7 - May 31 at 8:33 AM logoMarina Biotech to Introduce Its Therapeutic Microbiome Programs Against Gastrointestinal Diseases - May 30 at 10:00 AM logoMarina Biotech to Participate in Joseph Gunnar's Pioneers 2017 Conference on May 2 - April 27 at 7:11 PM logoMarina Biotech, Inc. (MRNA) CEO Joseph W. Ramelli Acquires 35,500 Shares - April 7 at 8:17 PM logoMarina Biotech Provides Business Update - April 7 at 11:19 AM logoJoseph W. Ramelli Purchases 97,550 Shares of Marina Biotech, Inc. (MRNA) Stock - April 5 at 9:15 PM logoMarina Biotech Signs Definitive Agreement with Windlas Healthcare to Manufacture IT-102 FDC Bi-Layer Tablet - April 3 at 10:06 AM logoMarina Biotech to Present Data on IT-102 and IT-103 at 2017 American Association for Cancer Research Annual Meeting - March 29 at 9:42 AM logoMarina Biotech to Present Data on Vascular Resistance and Cancer at the Endocrine Society Annual Meeting on April 1 - March 24 at 6:38 PM logoMarina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at the Society of Toxicology 56th Annual Meeting on March 16 - March 13 at 10:16 AM logoMarina Biotech to Present New Data for IT-102 and IT-103 at the 7th International Conference on Fixed Combination in Cannes, France - March 2 at 9:27 AM logoMarina Biotech to Participate in the 29th Annual ROTH Conference - March 1 at 6:43 PM logoMarina Biotech Engages KCSA Strategic Communications as Investor Relations Counsel - February 28 at 10:13 AM logoMarina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer - February 21 at 6:16 PM logoMarina Biotech Announces Key Additions to its Executive Management Team - February 14 at 8:15 PM logoMARINA BIOTECH, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Change in Directors or Principal Off - February 14 at 8:15 PM logoMarina Biotech Completes Share Issuance at a Valuation of $0.29 Per Share - February 10 at 7:32 PM logoMarina Biotech Announces a License Agreement to SMARTICLES - February 7 at 7:58 PM logo10:28 am Marina Biotech (thinly-traded) entered into a license agreement regarding its SMARTICLES platform; could receive up to $90 mln in success based milestones - February 7 at 7:58 PM logoMARINA BIOTECH, INC. Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statements a - January 28 at 1:50 AM logoMarina Biotech Granted European Claims Covering Bacteria Mediated Gene Silencing - January 3 at 10:46 AM logoMarina Biotech to Update Its tkRNAi Clinical Program at Biotech Showcase - December 27 at 10:16 AM logoPhilippe P. Calais to Join Marina Biotech's Board of Directors - December 14 at 7:19 PM logoMARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events - December 14 at 7:19 PM logoMARINA BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Dis - November 18 at 5:51 PM logoMarina Biotech (MRNA) to Merge with IthenaPharma - November 16 at 9:56 AM logoMARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers - August 1 at 9:17 AM logoMARINA BIOTECH, INC. Files SEC form 8-K, Other Events - June 24 at 9:17 AM logoMARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits - June 2 at 9:58 AM



Marina Biotech (MRNA) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by Staff